Logo - springer
Slogan - springer

Life Sciences - Animal Sciences | Integration of Pharmaceutical Discovery and Development - Case Histories

Integration of Pharmaceutical Discovery and Development

Case Histories

Series: Pharmaceutical Biotechnology, Vol. 11

Borchardt, R.T., Freidinger, R.M., Sawyer, T.K., Smith, P.L. (Eds.)

1998, XXIX, 610 p.

Available Formats:
eBook
Information

Springer eBooks may be purchased by end-customers only and are sold without copy protection (DRM free). Instead, all eBooks include personalized watermarks. This means you can read the Springer eBooks across numerous devices such as Laptops, eReaders, and tablets.

You can pay for Springer eBooks with Visa, Mastercard, American Express or Paypal.

After the purchase you can directly download the eBook file or read it online in our Springer eBook Reader. Furthermore your eBook will be stored in your MySpringer account. So you can always re-download your eBooks.

 
$279.00

(net) price for USA

ISBN 978-0-306-47384-5

digitally watermarked, no DRM

Included Format: PDF

download immediately after purchase


learn more about Springer eBooks

add to marked items

Hardcover
Information

Hardcover version

You can pay for Springer Books with Visa, Mastercard, American Express or Paypal.

Standard shipping is free of charge for individual customers.

 
$349.00

(net) price for USA

ISBN 978-0-306-45743-2

free shipping for individuals worldwide

usually dispatched within 3 to 5 business days


add to marked items

Softcover
Information

Softcover (also known as softback) version.

You can pay for Springer Books with Visa, Mastercard, American Express or Paypal.

Standard shipping is free of charge for individual customers.

 
$349.00

(net) price for USA

ISBN 978-1-4419-3288-4

free shipping for individuals worldwide

usually dispatched within 3 to 5 business days


add to marked items

In the late 1980s, it became painfully evident to the pharmaceutical industry that the old paradigm of drug discovery, which involved highly segmented drug - sign and development activities, would not produce an acceptable success rate in the future. Therefore, in the early 1990s a paradigm shift occurred in which drug design and development activities became more highly integrated. This new str- egy required medicinal chemists to design drug candidates with structural f- tures that optimized pharmacological (e. g. , high affinity and specificity for the target receptor), pharmaceutical (e. g. , solubility and chemical stability), bioph- maceutical (e. g. , cell membrane permeability), and metabolic/pharmacokinetic (e. g. , metabolic stability, clearance, and protein binding) properties. Successful implementation of this strategy requires a multidisciplinary team effort, incl- ing scientists from drug design (e. g. , medicinal chemists, cell biologists, en- mologists, pharmacologists) and drug development (e. g. , analytical chemists, pharmaceutical scientists, physiologists, and molecular biologists representing the disciplines of pharmaceutics, biopharmaceutics, and pharmacokinetics/drug metabolism). With this new, highly integrated approach to drug design now widely utilized by the pharmaceutical industry, the editors of this book have provided the sci- tific community with case histories to illustrate the nature of the interdisciplinary interactions necessary to successfully implement this new approach to drug d- covery. In the first chapter, Ralph Hirschmann provides a historical perspective of why this paradigm shift in drug discovery has occurred.

Content Level » Research

Keywords » Nucleoside - chemistry - development - metabolism - pharmaceutical - receptor

Related subjects » Animal Sciences - Biochemistry & Biophysics

Table of contents 

Introduction; R. Hirschmann. Renin Inhibitors; S.H. Rosenberg, H.D. Kleinert. The Discovery and Development of Angiotensin II Antagonists; D.J. Carini, et al. Development of an Orally Active Tripeptide Arginal Thrombin Inhibitor; R.T. Shuman, P.D. Gesellchen. Discovery and Development of an Endothelin-A Receptor Selective Antagonist PD 156707; A.M. Doherty, A.C.G. Uprichard. Endothelin Receptor Antagonists; J.D. Elliott, et al. LHRH Antagonists; F. Haviv, et al. LHRH Agonists; K.W. Funk, et al. Discovery and Development of Somatostatin Agonists; P. Marbach, et al. Factors Impacting the Delivery of Therapeutic Levels of Pyrone-Based HIV Protease Inhibitors;; G.E. Padbury, et al. The Integration of Medicinal Chemistry, Drug Metabolism, and Pharmaceutical Research and Development in Drug Discovery and Development: The Story of Crixivan®, an HIV Protease Inhibitor; J.H. Lin, et al. De Novo Design and Discovery of Cyclic HIV Protease Inhibitors Capable of Displacing the Active-Site Structural Water Molecule; G.V. De Lucca, et al. Discovery and Development of the BHAP Nonnucleoside Reverse Transcriptase Inhibitor Delaviridine Mesylate; W.J. Adams, et al. 12 Additional Chapters. Index.

Popular Content within this publication 

 

Articles

Read this Book on Springerlink

Services for this book

New Book Alert

Get alerted on new Springer publications in the subject area of Animal Physiology.